The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies

The c-Met receptor is a therapeutically actionable target in non-small-cell lung cancer (NSCLC), with one approved drug and several agents in development. Most suitable biomarkers for patient selection include c-Met amplification and exon-14 skipping. Our retrospective study focused on the frequency...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Der Steen, Nele, Zwaenepoel, Karen, Mazzaschi, Giulia, A. Luirink, Rosa, P. Geerke, Daan, Op de Beeck, Ken, Hermans, Christophe, Tiseo, Marcello, Van Schil, Paul, Lardon, Filip, Germonpré, Paul, Rolfo, Christian, Giovannetti, Elisa, J. Peters, Godefridus, Pauwels, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943481/
https://www.ncbi.nlm.nih.gov/pubmed/31817278
http://dx.doi.org/10.3390/molecules24244443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943481/
https://www.ncbi.nlm.nih.gov/pubmed/31817278
http://dx.doi.org/10.3390/molecules24244443

Ejemplares similares